Quiet neurodegenerative disease startup secures $100M from unnamed investors
A nine-figure raise is a lot of money for private biotechs, and something that many are eager to publicize. But one startup is keeping its mouth almost completely shut about a new funding round, instead drawing in an air of mystery.
Foster City, CA-based TrueBinding, focusing on diseases such as Alzheimer’s, stroke and cancer, quietly disclosed that it had raised $100 million late last week, issuing only the following statement:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.